Literature DB >> 10585405

Utrophin lacks the rod domain actin binding activity of dystrophin.

K J Amann1, A W Guo, J M Ervasti.   

Abstract

We previously identified a cluster of basic spectrin-like repeats in the dystrophin rod domain that binds F-actin through electrostatic interactions (Amann, K. J., Renley, B. A., and Ervasti, J. M. (1998) J. Biol. Chem. 273, 28419-28423). Because of the importance of actin binding to the presumed physiological role of dystrophin, we sought to determine whether the autosomal homologue of dystrophin, utrophin, shared this rod domain actin binding activity. We therefore produced recombinant proteins representing the cluster of basic repeats of the dystrophin rod domain (DYSR11-17) or the homologous region of the utrophin rod domain (UTROR11-16). Although UTROR11-16 is 64% similar and 41% identical to DYSR11-17, UTROR11-16 (pI = 4. 86) lacks the basic character of the repeats found in DYSR11-17 (pI = 7.44). By circular dichroism, gel filtration, and sedimentation velocity analysis, we determined that each purified recombinant protein had adopted a stable, predominantly alpha-helical fold and existed as a highly soluble monomer. DYSR11-17 bound F-actin with an apparent K(d) of 7.3 +/- 1.3 microM and a molar stoichiometry of 1:5. Significantly, UTROR11-16 failed to bind F-actin at concentrations as high as 100 microM. We present these findings as further support for the electrostatic nature of the interaction of the dystrophin rod domain with F-actin and suggest that utrophin interacts with the cytoskeleton in a manner distinct from dystrophin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585405     DOI: 10.1074/jbc.274.50.35375

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Chloride channel activity of ClC-2 is modified by the actin cytoskeleton.

Authors:  N Ahmed; M Ramjeesingh; S Wong; A Varga; E Garami; C E Bear
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

2.  Quadriceps myopathy caused by skeletal muscle-specific ablation of β(cyto)-actin.

Authors:  Kurt W Prins; Jarrod A Call; Dawn A Lowe; James M Ervasti
Journal:  J Cell Sci       Date:  2011-02-15       Impact factor: 5.285

Review 3.  Regulation of actin cytoskeleton dynamics in cells.

Authors:  Sung Haeng Lee; Roberto Dominguez
Journal:  Mol Cells       Date:  2010-04       Impact factor: 5.034

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

5.  Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle.

Authors:  Inna N Rybakova; Jitandrakumar R Patel; Kay E Davies; Peter D Yurchenco; James M Ervasti
Journal:  Mol Biol Cell       Date:  2002-05       Impact factor: 4.138

6.  Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle.

Authors:  Laurin M Hanft; Inna N Rybakova; Jitandrakumar R Patel; Jill A Rafael-Fortney; James M Ervasti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-24       Impact factor: 11.205

7.  Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Dyanna Melo; Bo Bao; Nhu Trieu; Yoshitaka Mizobe; Rika Maruyama; Kamel Mamchaoui; Jun Tanihata; Yoshitsugu Aoki; Shin'ichi Takeda; Vincent Mouly; William Duddy; Toshifumi Yokota
Journal:  Mol Ther       Date:  2019-07-26       Impact factor: 11.454

8.  Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion.

Authors:  T Ort; S Voronov; J Guo; K Zawalich; S C Froehner; W Zawalich; M Solimena
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

9.  The carboxy-terminal third of dystrophin enhances actin binding activity.

Authors:  Davin M Henderson; Ava Yun Lin; David D Thomas; James M Ervasti
Journal:  J Mol Biol       Date:  2011-12-28       Impact factor: 5.469

Review 10.  Optimizing exon skipping therapies for DMD.

Authors:  T Yokota; W Duddy; T Partridge
Journal:  Acta Myol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.